Logo image of INO

INOVIO PHARMACEUTICALS INC (INO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:INO - US45773H4092 - Common Stock

1.74 USD
-0.02 (-1.14%)
Last: 12/31/2025, 8:07:49 PM
1.7425 USD
+0 (+0.14%)
After Hours: 12/31/2025, 8:07:49 PM
Fundamental Rating

1

Overall INO gets a fundamental rating of 1 out of 10. We evaluated INO against 530 industry peers in the Biotechnology industry. INO may be in some trouble as it scores bad on both profitability and health. INO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year INO has reported negative net income.
INO had a negative operating cash flow in the past year.
INO had negative earnings in each of the past 5 years.
INO had a negative operating cash flow in each of the past 5 years.
INO Yearly Net Income VS EBIT VS OCF VS FCFINO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

The Return On Assets of INO (-155.78%) is worse than 84.91% of its industry peers.
Industry RankSector Rank
ROA -155.78%
ROE N/A
ROIC N/A
ROA(3y)-84.69%
ROA(5y)-69.23%
ROE(3y)-132.51%
ROE(5y)-101.92%
ROIC(3y)N/A
ROIC(5y)N/A
INO Yearly ROA, ROE, ROICINO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

INO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INO Yearly Profit, Operating, Gross MarginsINO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K -50K

More info and screens

0

2. Health

2.1 Basic Checks

INO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, INO has more shares outstanding
INO has more shares outstanding than it did 5 years ago.
INO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INO Yearly Shares OutstandingINO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
INO Yearly Total Debt VS Total AssetsINO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

INO has an Altman-Z score of -40.29. This is a bad value and indicates that INO is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -40.29, INO is doing worse than 89.81% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -40.29
ROIC/WACCN/A
WACC8.57%
INO Yearly LT Debt VS Equity VS FCFINO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

INO has a Current Ratio of 0.79. This is a bad value and indicates that INO is not financially healthy enough and could expect problems in meeting its short term obligations.
INO has a Current ratio of 0.79. This is amonst the worse of the industry: INO underperforms 87.36% of its industry peers.
INO has a Quick Ratio of 0.79. This is a bad value and indicates that INO is not financially healthy enough and could expect problems in meeting its short term obligations.
INO has a Quick ratio of 0.79. This is amonst the worse of the industry: INO underperforms 86.98% of its industry peers.
Industry RankSector Rank
Current Ratio 0.79
Quick Ratio 0.79
INO Yearly Current Assets VS Current LiabilitesINO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

INO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.79%, which is quite impressive.
INO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -10.55%.
INO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -44.44% yearly.
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.25%
Revenue 1Y (TTM)-10.55%
Revenue growth 3Y-50.31%
Revenue growth 5Y-44.44%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 16.59% on average over the next years. This is quite good.
INO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 356.19% yearly.
EPS Next Y42.3%
EPS Next 2Y27.98%
EPS Next 3Y24.99%
EPS Next 5Y16.59%
Revenue Next Year-33.27%
Revenue Next 2Y1092.62%
Revenue Next 3Y796.87%
Revenue Next 5Y356.19%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INO Yearly Revenue VS EstimatesINO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
INO Yearly EPS VS EstimatesINO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INO Price Earnings VS Forward Price EarningsINO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INO Per share dataINO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

INO's earnings are expected to grow with 24.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.98%
EPS Next 3Y24.99%

More info and screens

0

5. Dividend

5.1 Amount

INO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

INOVIO PHARMACEUTICALS INC

NASDAQ:INO (12/31/2025, 8:07:49 PM)

After market: 1.7425 +0 (+0.14%)

1.74

-0.02 (-1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)03-16 2026-03-16/amc
Inst Owners36.08%
Inst Owner Change103.66%
Ins Owners0.4%
Ins Owner Change0.13%
Market Cap119.54M
Revenue(TTM)182.30K
Net Income(TTM)-108.09M
Analysts80
Price Target7.79 (347.7%)
Short Float %13.81%
Short Ratio6.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-51.35%
Min EPS beat(2)-103.56%
Max EPS beat(2)0.86%
EPS beat(4)3
Avg EPS beat(4)-7.17%
Min EPS beat(4)-103.56%
Max EPS beat(4)44.99%
EPS beat(8)5
Avg EPS beat(8)-3.62%
EPS beat(12)6
Avg EPS beat(12)-4.36%
EPS beat(16)7
Avg EPS beat(16)-6.74%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11%
EPS NY rev (1m)-20.91%
EPS NY rev (3m)-20.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-9.95%
Revenue NY rev (3m)-2.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 655.72
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.49
EYN/A
EPS(NY)-1.45
Fwd EYN/A
FCF(TTM)-1.3
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS0
BVpS-0.11
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -155.78%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-84.69%
ROA(5y)-69.23%
ROE(3y)-132.51%
ROE(5y)-101.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.48%
Cap/Sales 85.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.79
Quick Ratio 0.79
Altman-Z -40.29
F-Score3
WACC8.57%
ROIC/WACCN/A
Cap/Depr(3y)20.92%
Cap/Depr(5y)27.95%
Cap/Sales(3y)90.66%
Cap/Sales(5y)72.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.25%
EPS Next Y42.3%
EPS Next 2Y27.98%
EPS Next 3Y24.99%
EPS Next 5Y16.59%
Revenue 1Y (TTM)-10.55%
Revenue growth 3Y-50.31%
Revenue growth 5Y-44.44%
Sales Q2Q%N/A
Revenue Next Year-33.27%
Revenue Next 2Y1092.62%
Revenue Next 3Y796.87%
Revenue Next 5Y356.19%
EBIT growth 1Y24.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y33.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.54%
OCF growth 3YN/A
OCF growth 5YN/A

INOVIO PHARMACEUTICALS INC / INO FAQ

Can you provide the ChartMill fundamental rating for INOVIO PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 1 / 10 to INO.


What is the valuation status of INOVIO PHARMACEUTICALS INC (INO) stock?

ChartMill assigns a valuation rating of 1 / 10 to INOVIO PHARMACEUTICALS INC (INO). This can be considered as Overvalued.


Can you provide the profitability details for INOVIO PHARMACEUTICALS INC?

INOVIO PHARMACEUTICALS INC (INO) has a profitability rating of 0 / 10.


Can you provide the financial health for INO stock?

The financial health rating of INOVIO PHARMACEUTICALS INC (INO) is 0 / 10.


What is the expected EPS growth for INOVIO PHARMACEUTICALS INC (INO) stock?

The Earnings per Share (EPS) of INOVIO PHARMACEUTICALS INC (INO) is expected to grow by 42.3% in the next year.